Work

Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia

Year: 2011

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v118.21.2951.2951

Authors: Steven P Treon, Christina K Tripsas, Leukothea Ioakimidis, Diane Warren, Christopher Patterson, Leonard Heffner, Herbert Eradat, Stephanie A. Gregory, Sheeba Thomas, Ranjana Advani, Rachid Baz, Ashraf Z. Badros, Jeffrey Matous, Kenneth C. Anderson, Irene M. Ghobrial

Institutions: Harvard University, Dana-Farber Cancer Institute, Emory University, Winship Cancer Institute, University of California, Los Angeles, Rush University Medical Center, The University of Texas MD Anderson Cancer Center, Stanford University, Moffitt Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Rocky Mountain Cancer Centers

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4232133662

FWCI: 1.01

Cites:

Cited by: 13

Related to: 10